Search Results

You are looking at 41 - 50 of 530 items for :

  • "pathology" x
  • Refine by Access: All x
Clear All
Full access

Laura J. Libby, Navneet Narula, Helen Fernandes, James F. Gruden, David J. Wolf, and Daniel M. Libby

Panel; Life Technologies, Inc., Grand Island, NY) showed that the patient harbored the KIT M541L variant in both the lymphangiomatosis and normal lung, suggesting the possibility of germline Figure 2. Surgical pathology. (A) Immunostain for D2

Full access

Christopher K. Bichakjian, Thomas Olencki, Sumaira Z. Aasi, Murad Alam, James S. Andersen, Rachel Blitzblau, Glen M. Bowen, Carlo M. Contreras, Gregory A. Daniels, Roy Decker, Jeffrey M. Farma, Kris Fisher, Brian Gastman, Karthik Ghosh, Roy C. Grekin, Kenneth Grossman, Alan L. Ho, Karl D. Lewis, Manisha Loss, Daniel D. Lydiatt, Jane Messina, Kishwer S. Nehal, Paul Nghiem, Igor Puzanov, Chrysalyne D. Schmults, Ashok R. Shaha, Valencia Thomas, Yaohui G. Xu, John A. Zic, Karin G. Hoffmann, and Anita M. Engh

, 88 , 107 – 110 although a few studies have used other neuroendocrine markers. 111 Pathology Report Synoptic Reporting: Both historically and currently, consistent synoptic reporting of histopathologic parameters for MCCs is not widespread

Full access

George D. Demetri, Robert S. Benjamin, Charles D. Blanke, Jean-Yves Blay, Paolo Casali, Haesun Choi, Christopher L. Corless, Maria Debiec-Rychter, Ronald P. DeMatteo, David S. Ettinger, George A. Fisher, Christopher D. M. Fletcher, Alessandro Gronchi, Peter Hohenberger, Miranda Hughes, Heikki Joensuu, Ian Judson, Axel Le Cesne, Robert G. Maki, Michael Morse, Alberto S. Pappo, Peter W. T. Pisters, Chandrajit P. Raut, Peter Reichardt, Douglas S. Tyler, Annick D. Van den Abbeele, Margaret von Mehren, Jeffrey D. Wayne, and John Zalcberg

diagnostics, pathology, radiation oncology, and surgery to discuss the optimal approach to care for patients with GIST at all stages of the disease. The GIST Task Force is composed of NCCN faculty and other key experts from the United States, Europe, and

Full access

Neha Mehta-Shah and Paola Ghione

opting for removal. Understanding who is at risk, recognizing the presenting features, and, when necessary, performing a thorough and expert pathology evaluation are essential to accurately diagnose BIA-ALCL or exclude the diagnosis as conclusively as

Full access

Katya Losk, Ines Vaz-Luis, Kristen Camuso, Rafael Batista, Max Lloyd, Mustafa Tukenmez, Mehra Golshan, Nancy U. Lin, and Craig A. Bunnell

influence the timing of chemotherapy initiation. These processes include referral from surgery to medical oncology, postoperative appointment scheduling, pathology turnaround time, and the role of additional testing, such as Oncotype DX (Genomic Health

Full access

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Linda Farkas, Ignacio Garrido-Laguna, Jean L. Grem, Andrew Gunn, J. Randolph Hecht, Sarah Hoffe, Joleen Hubbard, Steven Hunt, Kimberly L. Johung, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, and Lisa A. Gurski

laboratories that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform highly complex molecular pathology testing. 62 No specific testing methodology is recommended. 63 The three genes can be tested

Full access

John P. Sherbeck, Lili Zhao, and Richard W. Lieberman

The pathologic evaluation of lymph nodes (LNs) for metastatic disease plays an important role in the surgical staging of nearly all solid-organ malignancies. Nodal tissue is evaluated by pathology either as part of an en bloc resection or as

Full access

Nalan Nese, Ruta Gupta, Matthew H. T. Bui, and Mahul B. Amin

Edited by Kerrin G. Robinson

Novartis, Inc. References 1 Sesterhenn IA . Urothelial carcinoma in situ . In: Eble J Sauter G Epstein J Sesterhenn I , eds. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Urinary System and

Full access

Stephen B. Edge

Modern series define a risk of local recurrence after BCT of 2% to 5%, about the same as with mastectomy. 3 , 4 The improvement is partly due to improved standards in surgery, radiation oncology, and pathology. However, it is primarily due to the use of

Full access

Christos Vaklavas, John R. Ross, Lisle M. Nabell, Andres Forero, Martin J. Heslin, and Tina E. Wood

family members affected by the same or similar diagnoses across consecutive generations. This report presents the case of a patient without significant family history but with an unusual constellation of malignancies and pathologies, which prompted